The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Open accessAbstract
IMPORTANCE: The programmed death 1 (PD-1) pathway limits immune responses to melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody pembrolizumab. OBJECTIVE: To characterize the association of pembrolizumab with tumor response and overall survival among patients with advanced melanoma. DESIGN, SETTINGS, AND PARTICIPANTS: Open-label, multicohort, phase 1b clinical trials (enrollment, December 2011-September 2013). Median duration of follow-up was 21 months. The study was performed in academic medical centers in Australia, Canada, France, and the United States. Eligible patients were aged 18 years and older and had advanced or metastatic melanoma. Data were pooled from 655 enrolled patients (135 from a nonrandomized cohort [n = 87 ipilimumab naive; n = 48 ipilimumab treated] and 520 from randomized cohorts [n = 226 ipilimumab naive; n = 294 ipilimumab treated]). Cutoff dates were April 18, 2014, for safety analyses and October 18, 2014, for efficacy analyses. EXPOSURES: Pembrolizumab 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 2 mg/kg every 3 weeks continued until disease progression, intolerable toxicity, or investigator decision. MAIN OUTCOMES AND MEASURES: The primary end point was confirmed objective response rate (best overall response of complete response or partial response) in patients with measurable disease at baseline per independent central review. Secondary end points included toxicity, duration of response, progression-free survival, and overall survival. RESULTS: Among the 655 patients (median [range] age, 61 [18-94] years; 405 [62%] men), 581 had measurable disease at baseline. An objective response was reported in 194 of 581 patients (33% [95% CI, 30%-37%]) and in 60 of 133 treatment-naive patients (45% [95% CI, 36% to 54%]). Overall, 74% (152/205) of responses were ongoing at the time of data cutoff; 44% (90/205) of patients had response duration for at least 1 year and 79% (162/205) had response duration for at least 6 months. Twelve-month progression-free survival rates were 35% (95% CI, 31%-39%) in the total population and 52% (95% CI, 43%-60%) among treatment-naive patients. Median overall survival in the total population was 23 months (95% CI, 20-29) with a 12-month survival rate of 66% (95% CI, 62%-69%) and a 24-month survival rate of 49% (95% CI, 44%-53%). In treatment-naive patients, median overall survival was 31 months (95% CI, 24 to not reached) with a 12-month survival rate of 73% (95% CI, 65%-79%) and a 24-month survival rate of 60% (95% CI, 51%-68%). Ninety-two of 655 patients (14%) experienced at least 1 treatment-related grade 3 or 4 adverse event (AE) and 27 of 655 (4%) patients discontinued treatment because of a treatment-related AE. Treatment-related serious AEs were reported in 59 patients (9%). There were no drug-related deaths. CONCLUSIONS AND RELEVANCE: Among patients with advanced melanoma, pembrolizumab administration was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months; grade 3 or 4 treatment-related AEs occurred in 14%. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01295827.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“In melanoma, anti-PD-1 treatment was more effective in patients with smaller tumors (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Both CTLA-4 and PD-1 act independently as brakes on CD3/CD28-dependent signaling, suggesting that underlying immune responses are required for checkpoint inhibitor treatment to take effect (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“For example, patients with smaller tumors or low serum lactate dehydrogenase (LDH) levels at baseline have a better prognosis and are also more likely to respond to anti-PD-1 treatment (66).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [66]
In the citing paper
“Patients more likely to benefit from checkpoint immunotherapy include those with tumors demonstrating a high density of somatic mutations, elevated PD-L1 expression and/or are enriched with IFNγ transcriptional profiles (8–13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [11]
In the citing paper
“Anti-PD-1 immunotherapy has shown efficacy in melanoma, but fewer than half of all melanoma patients treated with anti-PD-1 immunotherapy have a prolonged response5.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Research works printed but not linked: 4
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma. Lancet. 2014;384(9948):1109-1117.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002). Lancet Oncol. 2015;16(8):908-918.
- Joseph RW, Elassaiss-Schaap J, Wolchok JD, et al. Baseline tumor size (BTS) and PD-L1 expression are independently associated with clinical outcomes in patients (pts) with metastatic melanoma (MM) treated with pembrolizumab (pembro; MK-3475). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1188.
- Kluger HM, Sznol M, Callahan MK et al. Survival, response duration and activity by BRAF mutation status in a phase 1 trial of nivolumab (anti-PD-1; BMS-936558,ONO-4538) and ipilimumab concurrent therapy in advanced melanoma (MEL). Abstract presented at: Society for Melanoma Research 2014 Congress; November 13-16, 2014; Zurich, Switzerland. Pigment Cell Melanoma Res. 2014;27:1203.
Cited by
Sorted by citations
Items 601–700 of 1,000
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism
Jaafar, J., Fernández, E., Alwan, H., & Philippé, J. (2018) · Endocrine Connections · doi:10.1530/ec-18-0079 · Cited by 16
Kim, M.-S., Choi, C.-H., Kim, T., Lee, J., Lee, J., Bae, D., & Kim, B. (2018) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2018.61.4.524 · Cited by 14
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
Jiang, X., Li, L., Li, Y., & Li, Q. (2019) · Journal of Cancer · doi:10.7150/jca.26481 · Cited by 15
Cybulska-Stopa, B., Pacholczak‐Madej, R., Kamińska‐Winciorek, G., Ziętek, M., Czarnecka, A. M., Piejko, K., Galus, Ł., Ziółkowska, B., Kieszko, S., Kempa-Kamińska, N., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0217 · Cited by 15
Mani, M., Park, J. W., & Martin, T. F. J. (2025) · Cancers · doi:10.3390/cancers17111747 · Cited by 16
Time-varying pattern of recurrence risk for localized melanoma in China
Wen, X., Li, D., Zhao, J., Li, J., Yang, T., Ding, Y., Peng, R., Zhu, B., Huang, F., & Zhang, X. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-019-1775-5 · Cited by 13
Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fate
Burrack, A. L., Spartz, E. J., Rollins, M. R., Miller, E. A., Firulyova, M. M., Cruz-Hinojoza, E., Goldberg, M. F., Wang, I., Nanda, H. A., Shen, S., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03338-7 · Cited by 13
Adverse Ocular Effects of Systemic Medications
Green, M. B., & Duker, J. S. (2023) · Life · doi:10.3390/life13030660 · Cited by 14
Donini, C., Galvagno, F., Rotolo, R., Massa, A., Merlini, A., Scagliotti, G. V., Novello, S., Bironzo, P., Leuci, V., & Sangiolo, D. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02363-2 · Cited by 13
The application and mechanism of PD pathway blockade for cancer therapy
Wang, X., Huang, S., Zhang, Y., Zhu, L., & Wu, X. (2017) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2017-135187 · Cited by 13
Sobecki-Rausch, J., & Barroilhet, L. M. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0679-5 · Cited by 13
Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors
Yuan, W., Xiao, C., Lao, X., Zheng, L., & Kuang, D. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03637-1 · Cited by 13
Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program
Spanish Melanoma Group, González‐Cao, M., Arance, A. M., Piulats, J. M., Márquez‐Rodas, I., Manzano, J. L., Berrocal, A., Crespo, G., Rodríguez, D., Pérez-Ruiz, E., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1602-1 · Cited by 13
Pembrolizumab use for the treatment of advanced melanoma
Specenier, P. M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1309388 · Cited by 13
Wang, Y., Sun, H., Li, R., Wang, X., Cheng, Z., & Lou, N. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9753 · Cited by 13
From waterfall plots to spaghetti plots in early oncology clinical development
Mercier, F., Consalvo, N., Frey, N., Phipps, A., & Ribba, B. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1944 · Cited by 13
Intratumoral injection of dendritic cells overexpressing interleukin‑12 inhibits melanoma growth
Yao, W., Li, Y., Zeng, L., Zhang, X., Zhou, Z., Zheng, M., & Wan, H. (2019) · Oncology Reports · doi:10.3892/or.2019.7165 · Cited by 13
Review of Systemic Agents in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
Petersen, E. T., Ahmed, S., Chen, L. L., Silapunt, S., & Migden, M. R. (2019) · Future Oncology · doi:10.2217/fon-2019-0158 · Cited by 14
Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed
Tu, H., Zhang, Q., & Wu, Y.-L. L. C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.152 · Cited by 13
Hsueh, E. C., & Gorantla, K. C. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0054-1 · Cited by 12
Kiffin, R., Johansson, J., Bagge, R. O., & Martner, A. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.04.038 · Cited by 12
Clinical significance of plasma PD-L1+ exosomes in the management of diffuse large B cell lymphoma
Xu, P., Liu, J., Chen, H., Shang, L., Wang, F., Zhu, Y., Guo, Y., Li, F., Yan, F., Xie, X., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05259-6 · Cited by 12
Lee, J., Lee, W. T., Le, X. T., & Youn, Y. S. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00661-8 · Cited by 12
Zhang, X., Zheng, P., Meng, B., Zhuang, H., Lu, B., Yao, J., Han, F., & Luo, S. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01399-9 · Cited by 12
Dai, L., Yin, J., Xin, X., Yao, C., Tang, Y., Xia, X., Chen, Y., Lai, S., Lu, G., Huang, J., et al. (2025) · Cancer Imaging · doi:10.1186/s40644-025-00855-3 · Cited by 12
PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma
Yang, Y., Qi, F., Wei, C., Liu, J., Zhang, Y., Luan, W., & Gu, J. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00727-2 · Cited by 12
Systemic Therapy Options for Patients With Unresectable Melanoma
Yushak, M. L., Chapman, P. B., Robert, C., & Kudchadkar, R. R. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_174934 · Cited by 12
Self-citationLim, S. Y., & Rizos, H. (2018) · Mammalian Genome · doi:10.1007/s00335-018-9757-4 · Cited by 12
Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database
Conic, R. R. Z., Knackstedt, R. W., Sussman, T. A., Rambhia, S., Damiani, G. B., Funchain, P., Ko, J. S., & Gastman, B. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000672 · Cited by 12
Ligtenberg, K. G., Hu, J. K., Damsky, W., Olino, K. L., Kluger, H. M., Clune, J. E., Cowper, S. E., Panse, G., Leventhal, J. S., & Weiss, S. A. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.05.010 · Cited by 12
The Role of Neoadjuvant Therapy in Melanoma
Kelly, Z. R., Gorantla, V. C., & Davar, D. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00944-5 · Cited by 12
Multiple primary melanomas: Our experience
Ungureanu, L., Zboraș, I., Vasilovici, A. F., Vesa, Ș. C., Cosgarea, I., Cosgarea, R., & Șenilă, S. C. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9520 · Cited by 12
Naeser, Y., Helgadóttir, H., Brandberg, Y., Hansson, J., Bagge, R. O., Elander, N. O., Ingvar, C., Isaksson, K., Flygare, P., Nilsson, C., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07632-4 · Cited by 13
Identification and validation of inflammatory subtypes in intrahepatic cholangiocellular carcinoma
Gao, B., Wang, Y., Zhang, X., Jiang, H., Han, F., Li, C., & Lu, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05529-5 · Cited by 11
Sehl, M. E., & Wicha, M. S. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7493-1_16 · Cited by 11
Valério-Fernandes, Â., Fonseca, N. A., Gonçalves, N., Cruz, A. F., Pereira, M. I., Gregório, A. C., Moura, V., Ladeirinha, A. F., Alarcão, A., Gonçalves, J., et al. (2022) · Cancers · doi:10.3390/cancers14092217 · Cited by 11
Wu, Q., Xia, Y., Xiong, X., Duan, X., Pang, X., Zhang, F., Tang, S., Su, J., Wen, S., Mei, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1169608 · Cited by 11
Cured or Not? Long-term Outcomes of Immunotherapy Responders. Focus on Melanoma
Boutros, C., Belkadi-Sadou, D., Marchand, A., Roy, S., Routier, É., & Robert, C. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01429-x · Cited by 11
Self-citationClinical trials in gynecologic oncology: Past, present, and future
Annunziata, C. M., & Kohn, E. C. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.11.026 · Cited by 11
Cancer immunology and melanoma immunotherapy
Linck, R. D. M., Costa, R. L. D. P., & Garicochea, B. (2017) · Anais Brasileiros de Dermatologia · doi:10.1590/abd1806-4841.201756511 · Cited by 14
Apatinib mesylate tablet in the treatment of advanced malignant melanoma
Yang, L., Zhu, H., Luo, P., Chen, S., Xu, Y., & Wang, C. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s175507 · Cited by 11
Burdett, N., Hsu, K., Xiong, L., Rico, G. T., Beckmann, K., Karapetis, C. S., & Brown, M. P. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13177 · Cited by 11
Limited-duration anti-PD-1 therapy for patients with metastatic melanoma
Mäkelä, S., Kohtamäki, L. M., Jaakkola, M., Juteau, S., & Hernberg, M. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1716388 · Cited by 11
Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma
Christiansen, S. A., Khan, S. A., & Gibney, G. T. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000245 · Cited by 11
Lang, B., Wang, M., Zhang, Z., Fu, Y., Han, X., Hu, Q., Ding, H., Shang, H., & Jiang, Y. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04667-6 · Cited by 11
Ju, W., Cai, H., Zheng, W., Li, D., Zhang, W., Yang, X.-H., & Yan, Z. (2024) · Oncology Letters · doi:10.3892/ol.2024.14215 · Cited by 10
Application of nanomedicines in tumor immunotherapy
Gao, Z., Wan, D., Luo, M., & Wei, X. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae055 · Cited by 11
Wu, N., Zhang, Q., Tang, R., Deng, L., Cao, Y., Fu, B., Dong, H., Huang, Z., Wan, L., He, H., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c03394 · Cited by 10
Reprogramming Factors Remodel Melanoma Cell Phenotype by Changing Stat3 Expression
Wang, Y., Mou, Y., Zhang, H., Wang, X., Li, R., Cheng, Z., & Liu, X. (2017) · International Journal of Medical Sciences · doi:10.7150/ijms.21952 · Cited by 10
Effects of systemic targeted immunosuppressive therapy on ocular surface
Mukhtar, S., & Jhanji, V. (2022) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000860 · Cited by 10
Yamazaki, N., Shimizu, A., Ozaki, M., Hamada, M., Takeuchi, N., Ito, Y., & Maekawa, S. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16518 · Cited by 9
Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer
Al‐Shaebi, F., Safi, M., Algabri, Y. A., Al‐Azab, M., Al-Danakh, A., Alradhi, M., Reem, A., & Zhang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1099696 · Cited by 9
Multiple primary melanomas: A literature review
Apostu, A. P., Ungureanu, L., Halmágyi, S.-R., Trufin, I. I., & Șenilă, S. C. (2023) · Medicine · doi:10.1097/md.0000000000034378 · Cited by 10
Black Is the New Black: Prolapsing Primary Anorectal Melanoma
Jensen, C. W., & Kin, C. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4527-9 · Cited by 10
Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?
Guadagni, S., Fiorentini, G., Clementi, M., Palumbo, G., Palumbo, P., Chiominto, A., Baldoni, S., Masedu, F., Valenti, M., Tommaso, A. D., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112382 · Cited by 10
Gut Microbiome and the Response to Immunotherapy in Cancer
Stancu, A. L. (2018) · Discoveries · doi:10.15190/d.2018.4 · Cited by 12
Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?
Vera-Badillo, F., Tannock, I. F., & Booth, C. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02257 · Cited by 10
IL‐16 processing in sentinel node regulatory T cells is a factor in bladder cancer immunity
Krantz, D., Mints, M., Winerdal, M. E., Riklund, K., Rutishauser, D., Zubarev, R. A., Zirakzadeh, A. A., Alamdari, F. I., Johansson, M., Sherif, A. M., et al. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12926 · Cited by 10
Current strategies of virotherapy in clinical trials for cancer treatment
Lin, W., Zhao, Y., & Zhong, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26947 · Cited by 10
Sánchez‐Magraner, L., de la Fuente, M., Evans, C., Miles, J., Elexpe, A., Rodriguez-Astigarraga, M., Astigarraga, E., & Barreda‐Gómez, G. (2021) · Analytica—A Journal of Analytical Chemistry and Chemical Analysis · doi:10.3390/analytica2040015 · Cited by 10
Gu, Y., Shang, Q.-X., Zhuo, Y., Zhou, J., Liu, B., Wang, W., Che, G., & Chen, L.-Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.777686 · Cited by 10
A perspective on the impact of radiation therapy on the immune rheostat
McBride, W. H., Ganapathy, E., Lee, M.-H., Nesseler, J. P., Nguyen, C., & Schaue, D. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170272 · Cited by 10
Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma
Levine, L. S., Mahuron, K. M., Tsai, K. K., Wu, C., Mattis, D. M., Pauli, M. L., Oglesby, A., Lee, J., Spitzer, M. H., Krummel, M. F., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08648-7 · Cited by 10
Self-citationBhatia, S., & Thompson, J. A. (2016) · JAMA · doi:10.1001/jama.2016.4012 · Cited by 10
PD1 functions by inhibiting CD28‐mediated co‐stimulation
O’Donnell, J. S., Smyth, M. J., & Teng, M. W. L. (2017) · Clinical & Translational Immunology · doi:10.1038/cti.2017.15 · Cited by 10
Shinn, C. K., Saddawi‐Konefka, R., Salanga, C. L., Schokrpur, S., Gutkind, J. S., & Handel, T. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.24.650529 · Cited by 10
Wang, X., Wu, C., & Wei, H. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0039 · Cited by 9
Alvarez, J., & Smith, J. (2023) · Seminars in Colon and Rectal Surgery · doi:10.1016/j.scrs.2023.100990 · Cited by 8
Zhang, N., Chang, J., Liu, P., Tian, X., & Yu, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1400262 · Cited by 9
Leshem, R., Sefton, K. N., Wong, C. W., Lin, I., Isaac, D. T., Niepel, M., & Hurlstone, A. F. L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010683 · Cited by 11
Barjot, C., Gaillard, T., Seban, R., Darrigues, L., Loirat, D., Cabel, L., Féron, J.-G., Fourchotte, V., Couturaud, B., Bonneau, C., et al. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110511 · Cited by 10
“Dissecting the role of T cell exhaustion in cancer progression: a multifaceted approach“
Li, X., & Song, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1646292 · Cited by 12
Self-citationEfficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
Cheng, Z., Yang, C., Zhao, Q., Zhong, J., Zhang, J., Jin, R., Li, Y., Ta, N., Wu, D., Yuan, Z., et al. (2024) · Cancer Science · doi:10.1111/cas.16142 · Cited by 9
Liu, Q., Xing, H., Xiong, M., & Zhang, X. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202414327 · Cited by 9
Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis
Guadagni, S., Fiorentini, G., Clementi, M., Palumbo, G., Chiominto, A., Cappelli, S., Masedu, F., & Valenti, M. (2017) · Journal of Surgical Research · doi:10.1016/j.jss.2017.03.066 · Cited by 9
Gene Expression Profiling in Melanoma: Past Results and Future Potential
Knackstedt, R. W., Knackstedt, T., & Gastman, B. (2018) · Future Oncology · doi:10.2217/fon-2018-0631 · Cited by 9
Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
Chanal, J., Kramkimel, N., Ratour, C., Aractingi, S., Guégan, S., & Avril, M. (2019) · Dermatology · doi:10.1159/000492467 · Cited by 9
Guadagni, S., Fiorentini, G., Papasotiriou, I., Apostolou, P., Masedu, F., Sarti, D., Farina, A. R., Mackay, A. R., & Clementi, M. (2020) · BMC Research Notes · doi:10.1186/s13104-020-05021-5 · Cited by 9
Ji, W., Li, L., Zhou, S., Qiu, L., Qian, Z., Zhang, H., & Zhao, P. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1766473 · Cited by 9
Kim, Y., Kim, K., Lee, K. H., Kim, J., & Jung, W. (2020) · Scientific Reports · doi:10.1038/s41598-020-69082-z · Cited by 9
Pattern of disease and response to pembrolizumab in recurrent cervical cancer
Miller, K., Filippova, O. T., Hayes, S. A., Abu‐Rustum, N. R., Aghajanian, C. A., Broach, V. A., Ellenson, L. H., Selenica, P., Jewell, E. L., Kyi, C., et al. (2021) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2021.100831 · Cited by 9
The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma
Zhu, W., Lv, J., Xie, X., Tian, C., Liu, J., Zhou, H., Sun, C., Li, J., Hu, Z., & Li, X. (2021) · Immunology Letters · doi:10.1016/j.imlet.2021.11.002 · Cited by 9
Self-citationRozeman, E. A., Versluis, J. M., Moritz, R., Wilgenhof, S., van Thienen, J. V., Haanen, J. B. A. G., van den Heuvel, M. M., Blank, C. U., & van Rossum, H. H. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.06.001 · Cited by 10
McClure, E., Carr, M. J., & Zager, J. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1796646 · Cited by 9
Gu, Y., Zhang, H., Liu, Z., Xia, Y., Liang, B., & Liang, L. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13385 · Cited by 9
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Ghanem, S., Valecha, G. K., Hossri, S., Ibrahim, U., & Atallah, J. P. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1395019 · Cited by 9
Asai, Y., Yanagawa, N., Osakabe, M., Yamada, N., Sugimoto, R., Sato, A., Ito, K., Koike, Y., Tanji, T., Sakuraba, M., et al. (2023) · Journal of Surgical Oncology · doi:10.1002/jso.27487 · Cited by 8
Zhao, X., Li, L. S., Chen, P.-W., Cheng, D., Liu, B.-B., Zhao, M., & Shen, J. (2024) · Surfaces and Interfaces · doi:10.1016/j.surfin.2024.105132 · Cited by 8
Barham, W. T., Stagg, M. P., Mualla, R., Dileo, M. D., & Kansara, S. (2025) · Cancers · doi:10.3390/cancers17010144 · Cited by 8
Monaca, F., Gomez-Randulfe, I., Parreira, A. S. D. F. M., Longo, V., Galetta, D., Pilotto, S., Polidori, S., Cantale, O., Stefani, A., Vita, E., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115435 · Cited by 8
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer
Genta, S., Ghisoni, E., Giannone, G., Mittica, G., & Valabrega, G. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1425679 · Cited by 8
Howell, A. V., Gebregziabher, M., THIERS, B. H., Paulos, C. M., Wrangle, J. M., Hunt, K. J., & Wallace, K. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.09.023 · Cited by 9
Frelau, A., Jali, E., Campillo‐Gimenez, B., Pracht, M., Porneuf, M., Dinulescu, M., Edeline, J., Boussemart, L., & Lesimple, T. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000739 · Cited by 8
Markelic, M. B., Mojić, M., Drača, D., Jelača, S., Jović, Z., Purić, M., Koruga, D. L., Mijatović, S., & Maksimović‐Ivanić, D. (2023) · Nanomaterials · doi:10.3390/nano13030372 · Cited by 8
Wang, Q., Li, X., Qiu, J., He, Y., Wu, J., Li, J., Liu, W., & Han, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.04.004 · Cited by 8
Self-citationKwong, A., Sanlorenzo, M., Rappersberger, K., & Vujic, I. (2017) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-016-0535-1 · Cited by 8
Rapid onset type 1 diabetes associated with the programmed cell death‐1 inhibitor pembrolizumab
Boyle, V., Cundy, T., & Cutfield, R. G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14340 · Cited by 8
Systemic Therapies for Unresectable Locoregional Melanoma: A Significant Area of Need
Tie, E. N., Lai-Kwon, J. E., & Gyorki, D. E. (2019) · Melanoma Management · doi:10.2217/mmt-2019-0010 · Cited by 8
Exosomen: potenzielle Flüssigbiopsie bei Kopf-Hals-Karzinomen
Theodoraki, M., & Ludwig, S. (2020) · HNO · doi:10.1007/s00106-019-00806-y · Cited by 8
Metadata
- Authors
- Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., Gangadhar, T. C., Hersey, P., Dronca, R., Joseph, R. W., Zarour, H., Chmielowski, B., Lawrence, D. P., Algazi, A., Rizvi, N. A., Hoffner, B., Mateus, C., Gergich, K., Lindia, J. A., Giannotti, M., Li, X. N., Ebbinghaus, S., Kang, S. P., & Robert, C.
- Affiliations
- University of California, Los Angeles (US)
- Angeles Clinic and Research Institute (US)
- University of California, San Francisco (US)
- Dana-Farber Cancer Institute (US)
- Memorial Sloan Kettering Cancer Center (US)
- Westmead Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- South Texas Accelerated Research Therapeutics (US)
- The University of Texas MD Anderson Cancer Center (US)
- Moffitt Cancer Center (US)
- Abramson Cancer Center (US)
- The University of Sydney (AU)
- Mayo Clinic (US)
- Mayo Clinic in Florida (US)
- University of Pittsburgh (US)
- Massachusetts General Hospital (US)
- Institut Gustave Roussy (FR)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Ribas, Antoni
- ORCID
- Ribas, Antoni
- Hamid, Omid
- Daud, Adil
- Hodi, F. Stephen
- Wolchok, Jedd D.
- Kefford, Richard
- Joshua, Anthony M.
- Patnaik, Amita
- Hwu, Wen-Jen
- Weber, Jeffrey S.
- Hersey, Peter
- Dronca, Roxana
- Joseph, Richard W.
- Zarour, Hassane
- Chmielowski, Bartosz
- Lawrence, Donald P.
- Algazi, Alain
- Rizvi, Naiyer A.
- Mateus, Christine
- Li, Xiaoyun Nicole
- Robert, Caroline
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-04-19
- Volume
- 315
- Issue
- 15
- Pages
- 1600
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2338494814
- Cited by
- 1,069
- References
- 22
- Citations by year
- 2026: 33 · 2025: 66 · 2024: 67 · 2023: 99 · 2022: 63 · 2021: 123 · 2020: 139 · 2019: 139 · 2018: 145 · 2017: 153 · 2016: 39
- FWCI
- 85.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- pembrolizumab, advanced melanoma, metastatic melanoma, anti-PD-1 therapy, anti-PD-1 monoclonal antibody, objective response rate, overall survival, progression-free survival, duration of response, ipilimumab, immune checkpoint inhibitors, treatment-naive patients, treatment-emergent adverse events, immune-related adverse events, immune-related pneumonitis, immune-related colitis
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Algorithms, Antibodies, Monoclonal, Antineoplastic Agents, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Rate, Treatment Outcome, Disease Progression, Disease-Free Survival, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
